Physician profile
Judith Cooley
NPI 1003138678
$2,528.79
in general payments reported to CMS, 2019-2025
27 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.45 · 2022: $33.88 · 2023: $174 · 2024: $158 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,482.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $363.57 | 2022-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $238.26 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $218.34 | 2024-2025 | |
| Astellas Pharma US INC | $187.79 | 2023-2025 | Veozah |
| Abbvie INC. | $160.40 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.10 | 2024-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $134.63 | 2025 | Mounjaro, Kisunla |
| Glaxosmithkline, LLC. | $130.95 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $121.53 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $112.51 | 2025 | Auvelity, Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $94.57 | 2025 | |
| Amgen INC. | $93.32 | 2025 | Krystexxa, Otezla, Repatha |
| Dexcom, INC. | $86.86 | 2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $77.46 | 2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.83 | 2025 | Caplyta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $43.66 | 2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $43.03 | 2025 | Voquezna |
| Emd Serono, INC. | $36.71 | 2023 | Mavenclad |
| Corium, LLC | $28.21 | 2025 | Azstarys |
| Tris Pharma INC | $23.97 | 2025 | Dyanavel Xr |
| Abbott Laboratories | $22.12 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $19.68 | 2025 | Capvaxive, Gardasil 9 |
| Corcept Therapeutics | $19.32 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $17.48 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $16.97 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.91 | 2025 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $13.61 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Cooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.